Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti - 1 Jan 2012

Heneberg P

Abstract excerpt

The B-RAF kinase is among major targets of biological therapy of cancer. B-RAF acts in the MAP kinase pathway, being activated by any of the RAS G-proteins. Hyperactive B-RAF is typically detected in chemoresistant and radioresistant malignant metastatic melanoma. In this study, we focus on the reversible ATP-competitive inhibitor dabrafenib (GSK-2118436), which is now in phase III clinical trial for use in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to PTEN gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Imidazoles

Share to Melanoma

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 23102194

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].PMID 23102194Read ↗

Mutant B-Raf Kinase Inhibitors as Anticancer Agents.Semantic proximity Read ↗

A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.Semantic proximity Read ↗

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.Semantic proximity Read ↗

B-Raf Inhibition in the Clinic: Present and FutureSemantic proximity Read ↗

Recent advances in B-RAF inhibitors as anticancer agents.Semantic proximity Read ↗

Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.Semantic proximity Read ↗

A critical review of RAF inhibitors in BRAF-mutated glioma treatment.Semantic proximity Read ↗

Drug resistance in targeted cancer therapies with RAF inhibitorsSemantic proximity Read ↗

On the development of B-Raf inhibitors acting through innovative mechanisms.Semantic proximity Read ↗

The genesis of Zelboraf: targeting mutant B-Raf in melanoma.Semantic proximity Read ↗

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.Semantic proximity Read ↗

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.